At the press briefing on Monday, ASCO featured advances in lung and breast cancer treatment and prevention and new insight on the nation’s cancer drug shortages.
ASCO Annual Meeting
An updated blog from the 2013 ASCO Annual Meeting held in Chicago.
Advertisement
On Sunday, ASCO released data from five pivotal studies on reducing cervical cancer deaths worldwide, first therapies for two rare cancers, and treatment advances for breast and brain cancers.
Carol Aghajanian, MD, from the Memorial Sloan-Kettering Cancer Center, discusses a phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.
ASCO Highlights: T-DM1 vs capecitabine and lapatinib in HER2 breast cancer; axitinib in glioblastoma
By
An updated blog from the 2013 ASCO Annual Meeting held in Chicago.
In a press briefing on Saturday, ASCO highlighted important advances in treatment for multiple aggressive cancers, and new insight on HPV related cancer risk.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Orca-T Gains FDA Approval in Matched Donor Transplants
2
Q3 2026 Oncology Outlook: Key FDA Decisions to Watch
3
Advanced Renal Cell Carcinoma: Building a Personalized First-Line Treatment Algorithm
4
Experts Weigh Fixed-Duration Approaches in Frontline CLL
5